ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
Yvonne M. Golightly, PT, MS, PhD, Jill Halstead, BSc, MSc, PhD, MRCPod, John B. Arnold, PhD, Lara S. Chapman, MSc, BPod, Catherine J. Bowen, PhD, BPod, Marian T. Hannan, DSc, MPH, Hylton B. Menz, PhD, BPod, Kade L. Paterson, PhD, BPod, BAppSci(Hons) & Martin J. Thomas, PhD, MCSP |
Midfoot OA experts offer an overview of a common, but under-recognized, form of OA, & discuss quality of life impacts, treatments, clinical evaluation procedures & the critical need for further research.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
Teresa J. Brady, PhD, MACR, Basia Belza, PhD, RN, FAAN, FGSA, Kimberly Kimpton, PT, MACR, & Marian T. Hannan, DSc, MPH, MACR |
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
This year’s Rheumatic Disease Awareness Month encourages rheumatology professionals to collaborate with patients on physical activity routines that benefit their health.